416P Phase II study of 1st-line (1L) durvalumab (D) and platinum-etoposide (EP) in advanced large-cell neuroendocrine lung carcinoma (aLCNEC)

20260 citationsJournal Articlegold Open Access

Authors

Good health and well-being

Published in: ESMO Open

Volume 11, pp. 106730-106730

Field-Weighted Citation Impact: 0.00